Dong-A SOCIO Group’s affiliates, Dong-A ST, STPharm, and ESTGenoBio, announced on June 13 that they will participate in the 2025 BIO International Convention (BIO USA), taking place in Boston from June 16 to 19 (local time).
BIO USA, organized by the Biotechnology Innovation Organization (BIO), is the world’s largest biotech and pharmaceutical exhibition, drawing over 20,000 industry professionals from more than 70 countries annually. The event serves as a platform for sharing R&D pipeline updates, attracting investments, licensing technologies, and strengthening global partnerships through business meetings.
At this year’s event, Dong-A ST, STPharm, and ESTGenoBio will set up a joint booth to showcase their core technologies and strategies for entering international markets. Company executives, including Dong-A ST’s President of R&D Jae-hong Park, STPharm’s President Muje Seong, and ESTGenoBio’s CEO Gyeong-eun Choi, will lead direct business meetings and promotional activities on-site.
Dong-A ST will present 14 clinical-stage pipelines and 24 early to preclinical-stage pipelines across fields such as oncology, immuno-inflammatory diseases, neurology, and endocrinology. It will also unveil innovative research achievements in new modalities, including exosome-based drug delivery systems, mRNA-LNP technology, and AAV-mediated gene therapies. Its subsidiary, Aptus, will introduce its ADC linker platform ‘AbClick®’ and targeted therapies for gastric and pancreatic cancers, ‘AT-211 (DA-3501),’ engaging in new business discussions.
STPharm plans to showcase its core sgRNA synthesis technology for the CRISPR/Cas system, precise analytical capabilities, enzymatic hybrid approaches, and key drug candidates such as the first allosteric HIV-1 integrase inhibitor (STP0404) and treatments for advanced solid tumors (STP1002).
ESTGenoBio will highlight its compliance achievements, including passing FDA cGMP audits and obtaining EMA GMP certification. The company will promote its robust quality control, manufacturing capabilities, and services such as cGMP raw material production and prefilled syringe (PFS) contract manufacturing (CMO). It aims to expand annual PFS production capacity to 28 million units through upgraded bioproduction lines and new sterile filling facilities, with strategic plans for constructing a second plant of 35kL capacity to meet growing global demand.
A representative of Dong-A SOCIO Group stated, “Through BIO USA, we aim to showcase the unique technological strengths of Dong-A ES, STPharm, and ESTGenoBio to a global audience. Our goal is to achieve tangible results such as technology exports, investment attraction, and expanded international partnerships.”
